STOCK TITAN

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
conferences

SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced its participation in the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024, in Madrid. The company's Executive Vice President and Chief Medical Officer, Alexandra Kropotova, MD, MBA, will present on the topic 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.

SAB BIO is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D). The presentation will take place during the INNODIA EASD Symposium at 8:45 am in the Beijing Hall of the EASD Symposium, highlighting the company's innovative approach to T1D treatment.

SAB BIO (Nasdaq: SABS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 60° Congresso Annuale dell'Associazione Europea per lo Studio del Diabete il 9 settembre 2024 a Madrid. L'Executive Vice President e Chief Medical Officer dell'azienda, Alexandra Kropotova, MD, MBA, presenterà un intervento sul tema 'Proteggere le cellule beta pancreatiche con l'immunoterapia multi-target e multi-epitope: SAB-142'.

SAB BIO sta sviluppando una nuova piattaforma di immunoterapia utilizzando immunoglobulina anti-timosinica umana (hIgG) per ritardare l'insorgenza o la progressione del diabete di tipo 1 (T1D). La presentazione si svolgerà durante il Simposio INNODIA EASD alle 8:45 presso la Beijing Hall del Simposio EASD, mettendo in evidenza l'approccio innovativo dell'azienda nel trattamento del T1D.

SAB BIO (Nasdaq: SABS), una empresa biofarmacéutica en fase clínica, ha anunciado su participación en el 60° Congreso Anual de la Asociación Europea para el Estudio de la Diabetes el 9 de septiembre de 2024 en Madrid. La Vicepresidenta Ejecutiva y Directora Médica de la empresa, Alexandra Kropotova, MD, MBA, presentará sobre el tema 'Protegiendo las células beta pancreáticas con inmunoterapia multiobjetivo y multipéptido: SAB-142'.

SAB BIO está desarrollando una nueva plataforma de inmunoterapia utilizando inmunoglobulina anti-timosina humana (hIgG) para retrasar la aparición o progresión de diabetes tipo 1 (T1D). La presentación se llevará a cabo durante el Simposio INNODIA EASD a las 8:45 am en el Beijing Hall del Simposio EASD, destacando el enfoque innovador de la empresa en el tratamiento del T1D.

SAB BIO (나스닥: SABS)는 임상 단계의 생명공학 회사로, 2024년 9월 9일 마드리드에서 열리는 제60회 유럽 당뇨병 연구 협회 연례 회의에 참여할 것이라고 발표했습니다. 회사의 수석 부사장이자 최고 의료 책임자인 알렉산드라 크로포토바(MD, MBA)'다중 타겟 다중 에피토프 면역요법으로 췌장 베타 세포 보호: SAB-142' 주제로 발표할 예정입니다.

SAB BIO는 1형 당뇨병 (T1D)의 발병 또는 진행을 지연시키기 위해 인간 항-흉선 면역글로불린(hIgG)을 사용하는 혁신적인 면역요법 플랫폼을 개발하고 있습니다. 발표는 EASD 심포지엄의 Beijing Hall에서 오전 8시 45분에 INNODIA EASD 심포지엄 중에 진행되며, T1D 치료를 위한 회사의 혁신적인 접근법을 강조할 것입니다.

SAB BIO (Nasdaq: SABS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 60e Réunion Annuelle de l'Association Européenne pour l'Étude du Diabète qui se tiendra le 9 septembre 2024 à Madrid. La Vice-Présidente Exécutive et Directrice Médicale de l'entreprise, Alexandra Kropotova, MD, MBA, présentera sur le thème 'Protection des cellules bêta du pancréas par une immunothérapie multi-ciblée et multi-épitopes : SAB-142'.

SAB BIO développe une nouvelle plateforme d'immunothérapie utilisant des immunoglobulines anti-thymocytes humains (hIgG) pour retarder l'apparition ou la progression du diabète de type 1 (T1D). La présentation aura lieu lors du Symposium INNODIA EASD à 8h45 dans la salle Beijing du Symposium EASD, mettant en avant l'approche innovante de l'entreprise pour le traitement du T1D.

SAB BIO (Nasdaq: SABS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 60. Jahrestagung der Europäischen Gesellschaft für Diabetesforschung am 9. September 2024 in Madrid angekündigt. Die Executive Vice President und Chief Medical Officer des Unternehmens, Alexandra Kropotova, MD, MBA, wird zum Thema 'Schutz der insulinproduzierenden Betazellen durch Multi-Target- und Multi-Epitop-Immuntherapie: SAB-142' sprechen.

SAB BIO entwickelt eine neuartige Immuntherapie-Plattform mit menschlichem anti-thymozyten Immunoglobulin (hIgG), um den Ausbruch oder das Fortschreiten von Typ-1-Diabetes (T1D) zu verzögern. Die Präsentation findet während des INNODIA EASD Symposiums um 8:45 Uhr im Beijing Saal des EASD Symposiums statt und hebt den innovativen Ansatz des Unternehmens zur Behandlung von T1D hervor.

Positive
  • None.
Negative
  • None.

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present at the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024 in Madrid. SAB’s Executive Vice President and Chief Medical Officer Alexandra Kropotova, MD, MBA will present “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.”

Title:Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142”

Date & Time:

INNODIA EASD Symposium

September 9, 2024

8:45 am

Location: Beijing Hall of EASD Symposium

About the European Association for the Study of Diabetes

The European Association for the Study of Diabetes (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific program includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research.

About SAB-142

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical trials for type 1 diabetes, demonstrating the ability to slow down disease progression in patients with new or recent onset of Stage 3 type 1 diabetes.

Two clinical trials have shown that a single, low dose of 2.5mg/kg rabbit ATG has demonstrated the ability to modulate the body’s immune response to help slow beta cell destruction and preserve the ability of these cells to generate insulin, which the body needs to regulate blood sugar and carry out all human activities.

SAB-142, like rabbit ATG, directly targets multiple immune cells involved in destroying pancreatic beta cells. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells. However, most humans treated with rabbit ATG develop serum sickness and anti-drug antibodies from exposure to the rabbit-derived antibody. SAB-142 is a human antibody, intended to allow safe, consistent re-dosing for type 1 diabetes, a lifelong chronic disease, without the potential risk of inducing major adverse immune reactions that can occur with the administration of an animal ATG.

About SAB BIO

SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: www.SAB.bio and follow SAB on LinkedIn.

Forward-Looking Statements

Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the development and efficacy of our T1D program and other discovery programs.

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Media Relations:
khollon@sab.bio

Investor Relations:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com


FAQ

When and where will SAB BIO (SABS) present at the European Association for the Study of Diabetes Annual Meeting?

SAB BIO (SABS) will present on September 9, 2024, at 8:45 am in the Beijing Hall during the INNODIA EASD Symposium at the European Association for the Study of Diabetes 60th Annual Meeting in Madrid.

What is the title of SAB BIO's presentation at the EASD Annual Meeting?

The title of SAB BIO's presentation is 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.

Who will be presenting on behalf of SAB BIO (SABS) at the EASD Annual Meeting?

Alexandra Kropotova, MD, MBA, the Executive Vice President and Chief Medical Officer of SAB BIO, will be presenting at the EASD Annual Meeting.

What is SAB BIO (SABS) developing for type 1 diabetes treatment?

SAB BIO (SABS) is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).

SAB Biotherapeutics, Inc. Warrant

NASDAQ:SABSW

SABSW Rankings

SABSW Latest News

SABSW Stock Data

9.23M
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
MIAMI BEACH